Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT)-Reference-Cited by-同舟云学术

Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT)

Published:2011-01 Issue:1 Volume:102 Page:99-102
ISSN:1096-7192
Container-title:Molecular Genetics and Metabolism
language:en
Short-container-title:Molecular Genetics and Metabolism

Author:

Linthorst Gabor E.,Germain Dominique P.,Hollak Carla E.M.,Hughes Derralynn,Rolfs Arndt,Wanner Christoph,Mehta Atul

Publisher

Elsevier BV

Subject

Endocrinology,Genetics,Molecular Biology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference12 articles.

1. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/11/news_detail_000075.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1.

2. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/04/news_detail_001020.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1.

3. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/07/news_detail_001046.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1.

4. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease;Lubanda;Genet. Med.,2009

5. Summary of Product Characteristics Fabrazyme. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000370/WC500020547.pdf, accessed at Oct 12, 2010.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease;Frontiers in Genetics;2024-04-12

2. An expert consensus on the recommendations for the use of biomarkers in Fabry disease;Molecular Genetics and Metabolism;2023-06

3. New insights in efficacy of different ERT dosages in Fabry disease: Switch and switch-back studies data following agalsidase beta shortage. Update of systematic review;Genetics in Medicine Open;2023

4. Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative review;Cardiovascular Diagnosis and Therapy;2021-04

5. Treatment switch in Fabry disease- a matter of dose?;Journal of Medical Genetics;2020-06-10